Y Intercept Hong Kong Ltd Buys Shares of 39,469 Zimmer Biomet Holdings, Inc. $ZBH

Y Intercept Hong Kong Ltd bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, HoldingsChannel reports. The fund bought 39,469 shares of the medical equipment provider’s stock, valued at approximately $3,600,000.

Several other institutional investors also recently bought and sold shares of the company. Cobblestone Capital Advisors LLC NY boosted its stake in Zimmer Biomet by 14.0% in the second quarter. Cobblestone Capital Advisors LLC NY now owns 3,807 shares of the medical equipment provider’s stock valued at $347,000 after acquiring an additional 467 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in Zimmer Biomet by 2.0% in the second quarter. Envestnet Asset Management Inc. now owns 322,557 shares of the medical equipment provider’s stock valued at $29,420,000 after acquiring an additional 6,249 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Zimmer Biomet by 1.6% in the second quarter. Nisa Investment Advisors LLC now owns 64,323 shares of the medical equipment provider’s stock valued at $5,882,000 after acquiring an additional 1,036 shares in the last quarter. Wealthfront Advisers LLC boosted its stake in Zimmer Biomet by 28.2% in the second quarter. Wealthfront Advisers LLC now owns 4,877 shares of the medical equipment provider’s stock valued at $445,000 after acquiring an additional 1,074 shares in the last quarter. Finally, Resonant Capital Advisors LLC boosted its stake in Zimmer Biomet by 8.0% in the second quarter. Resonant Capital Advisors LLC now owns 4,771 shares of the medical equipment provider’s stock valued at $436,000 after acquiring an additional 354 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Trading Down 1.6%

Shares of Zimmer Biomet stock opened at $99.54 on Thursday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The firm has a fifty day moving average price of $101.69 and a 200 day moving average price of $97.61. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72. The stock has a market cap of $19.72 billion, a PE ratio of 24.22, a price-to-earnings-growth ratio of 2.33 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. During the same quarter last year, the company posted $2.01 earnings per share. The firm’s revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Insider Activity

In related news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.39% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. Canaccord Genuity Group reiterated a “hold” rating and set a $101.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, October 22nd. Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Rothschild & Co Redburn assumed coverage on shares of Zimmer Biomet in a research note on Thursday, September 18th. They set a “buy” rating and a $130.00 price objective for the company. Finally, Redburn Partners set a $130.00 price objective on shares of Zimmer Biomet in a research note on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $111.94.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.